This March, with his donor heart failing, Rathe's condition became critical when he lost consciousness and collapsed.
"We knew if we didn't move forward with the Total Artificial Heart, Greg would not survive," said John Um , MD, surgical director of cardiac transplantation and mechanical circulatory support at The Nebraska Medical Center.
To save Rathe's life, on March 14, Drs. Moulton and Um performed the state's first implant of the SynCardia Total Artificial Heart.
Now that he's on the road to recovery, Rathe's hopes for the future are simple: "Help take care of my son. He's only 4. So I can watch him grow up. Go back to work… live a normal life."
View news coverage of The Nebraska Medical Center's first implant -
Read press release from The Nebraska Medical Center -
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces b
|SOURCE SynCardia Systems, Inc.|
Copyright©2012 PR Newswire.
All rights reserved